Place: BioVendor R&D, Karasek 1767/1, Brno
Date: 12th—13th November 2024
PROGRAM 12th November:
11:30-12:15 LUNCH
Cinema hall
- 12:15-12:30 INTRODUCTORY INFORMATION – Hložánková, Hajdúch
- 12:30-13:00 Hajdúch (DP 11) Biomarkers and molecular diagnostics for personalized medicine
- 13:00-13:30 Vyklický/Kudová (DP 6) - Study of functional and behavioral consequences of disease-associated mutations in the NMDA receptor and potential rescue pharmacology
- 13:30-14:00 Nencka (DP 9) Novel (multi)targeted ligands of nuclear receptors for the therapy of the metabolic diseases
- 14:00-14:15 BREAK
- 14:15-14:45 Tichý (DP 3) Novel nucleoside analogues as potent anticancer drugs
- 14:45-15:15 Maloy Řezáčová (DP4) Theranostic applications of cancer specific carbonic anhydrases
- 15:15-15:45 Vrábel (DP 5) Development of chimeric antigen receptor modified immune cells for cancer immunotherapy
- 15:45-16:15 Martásek (DP 13) Biomedical prospecting of a life pigment: metabolic basis of inherited heme deficiency disorders
- 16:30-17:00 BOARD MEETING (onsite and/or online) (Decristoforo, Fusek, Hajdúch, Hauser, Martásek, Normanton, Perlík)
Room 21
- 13:00-14:00 ADMINISTRATION MEETING (onsite and/or online) Project managers of consortium
- 16:15-16:45 Optional excursion of Biovendor laboratories
- 18:00-20:00 DINNER (Alvin restaurace – Hudcova 2, Brno-Medlánky, 621 00)
PROGRAM 13th November:
Cinema hall
- 09:00-9:30 Janovská (DP 12) Casein kinase inhibitors for treatment of human cancers
- 9:30-10:00 Brož (DP 1) Development of informatic solutions enabling digitalization, interpretation and management of human genome data in clinical practice
- 10:00-10:30 Macek (DP 2) Artificial intelligence, telemedicine and machine learning system for clinical applications
- 10:30-11:00 Petřík (DP 10) Targeted molecular imaging of infection and cancer disorders
- 11:00-11:30 BREAK/LUNCH
- 11:30-12:00 Janeba (DP7) Purine nucleoside phosphorylase inhibitors for treatment of T-cell leukemia
- 12:30-13:00 Maletínská (DP 8) Interplay between anorexigenic and orexigenic peptides in Alzheimer’s-like pathology
